muscle, effects on cardiac metabolism, and vasoconstriction of blood vessels.' In addition, clinical studies demonstrating the efficiency of angiotensin converting enzyme (ACE) inhibitors in the treatment of heart failure,2 myocardial ischemia,3 4and hypertension5.6 suggest that Ang II directly promotes pathological cell growth that participates in remodeling of the failing heart. Several animal studies have implicated Ang II in cardiac hypertrophy associated with hypertension; for instance, in a rat model of "pressure-overload" cardiac hypertrophy, treatment with an ACE inhibitor prevented the increase in left ventricular mass with no effect on afterload,7 suggesting that the growth effects of Ang II are direct. Moreover, chronic infusion of Ang II into rats increased left ventricular mass, even when the pressor activity of Ang II was blocked or a subpressor dose of Ang II was used.8 Recent experiments using cultured embryonic chick cardiomyocytes lend further support to the hypothesis that Ang II can directly produce cellular hypertrophy.9"10 It has not been established whether Ang II also has a direct growth effect on nonmyocyte cells of the heart, although recent studies suggest that cardiac fibroblasts are a target for Ang II; for instance, treatment with the ACE inhibitor captopril prevented myocardial fibrosis in a rat model with renovascular hypertension" and with induced myocardial infarction.12 In the latter study, by guest on August 15, 2017
Presented in part at the 65th Scientific Sessions of the American Heart Association, New Orleans, La., November [16] [17] [18] [19] 1992 , and published in abstract form (Circulation 1992 muscle, effects on cardiac metabolism, and vasoconstriction of blood vessels.' In addition, clinical studies demonstrating the efficiency of angiotensin converting enzyme (ACE) inhibitors in the treatment of heart failure,2 myocardial ischemia,3 4and hypertension5.6 suggest that Ang II directly promotes pathological cell growth that participates in remodeling of the failing heart. Several animal studies have implicated Ang II in cardiac hypertrophy associated with hypertension; for instance, in a rat model of "pressure-overload" cardiac hypertrophy, treatment with an ACE inhibitor prevented the increase in left ventricular mass with no effect on afterload,7 suggesting that the growth effects of Ang II are direct. Moreover, chronic infusion of Ang II into rats increased left ventricular mass, even when the pressor activity of Ang II was blocked or a subpressor dose of Ang II was used. (2.5 gCi/ml), or [14C]uridine (0.2 ,Ci/ml) was added to the medium. For measuring rates of amino acid incorporation, nonlabeled phenylalanine (0.3 mM) was added to the culture medium to minimize variations in the specific activity of the precursor pool. Two or three plates from three separate dispersions were used for each experimental condition (control, Ang II, antagonist, and Ang II plus antagonist). At the end of incubation, cells were washed with PBS and lysed with 0.2 ml of 0.1 M NaOH-0.1% SDS. Macromolecules in the lysates were precipitated with 0.5 ml ice-cold 10% trichloroacetic acid. Precipitates were collected on GF/C filters (Whatman Inc., Clifton, N.J.) and washed three times with 10% trichloroacetic acid and three times with 70% ethanol. Radioactivity was measured with a Beckman LS3801 liquid scintillation counter. Preliminary studies established that incorporation of the radiolabels into the acid-precipitated cellular fraction was linear for 3 hours. Because cells were not growth-arrested, variability was observed in control incorporation of radiolabels, which ranged (in counts per minute per 35- Figure 1A (left) shows a phase-contrast photomicrograph of cardiac fibroblasts that were used in this study. The fibroblasts were mononucleated, bipolar, or multipolar cells, which appeared spread out on the dish. The cytosol was translucent, and the cell perimeter was not sharply defined. Rat aortic VSMCs exhibited a similar morphology, with the exception that many were multinucleated ( Figure 1A , right). Staining with antibody for smooth muscle-specific MHC demonstrated that VSMCs constituted a small proportion of the cells in culture ( Figure 1B, top left) . In 14 randomly chosen fields (total, 687 cells; magnification, x 320), the proportion of VSMCs was 4.68±1.04%. Rat aortic VSMCs served as a positive control for MHC staining ( Figure 1B (Figure 3, insert) .
Competitive binding experiments were performed to define the ligand specificity of the Ang II binding site.
As Figure 4 shows, Ang I, Ang In other cells, the plasma membrane AT, class of Ang II receptors has been shown to be coupled with G proteins.1624 This possibility was examined in cardiac fibroblasts by testing the ability of the nonhydrolyzable GTP analogue GMP-PNP to accelerate the displacement of bound radiolabeled Ang II by excess nonlabeled Ang II. As Figure 5 shows, GMP-PNP together with nonlabeled Ang II accelerated the displacement of 
Effects ofAng II on Intracellular Calcium
Increases in intracellular Ca>2 may be an important step in Ang II-mediated growth. As described for other cell types,' the AT1 receptor on cardiac fibroblasts was found to be coupled with increases in intracellular Ca`.
[Sar']Ang 11 (1 ,uM) 
Effect ofAng II on Cellular Growth
We next examined whether the Ang II receptor in cardiac fibroblasts is coupled with cellular growth. As Figure 7 shows, a 48-hour treatment of cardiac fibroblasts with 1 nM to 1 ,uM Growth-promoting effects of Ang II have been reported for other cell types, including cardiomyocytes,9,10 smooth muscle,30 a 3T3 fibroblast clone,3' and kidney proximal tubular cells.32 How the Ang II receptor is coupled with cellular growth has not been established, although Ang II has been shown to stimulate a number of intracellular signaling pathways that are also activated by other growth factors, such as phospholipase C and protein kinase C, elevation of cytosolic Ca2+, and the Na+-H1 exchanger with subsequent intracellular alkalinization.' Alternatively, the growth-promoting effects of Ang II on cardiac fibroblasts could be mediated indirectly through the induction of a growth factor, such as PDGF, as recently shown for VSMCs. 33 Collagen accumulation in the adventitia of the intramyocardial coronary arteries and myocardial interstitium is a hallmark of the remodeling process seen in left ventricular hypertrophy.1334 It has been proposed that this process may lead to diastolic and systolic dysfunction, ultimately leading to heart failure.35 Circumstantial evidence including the following has implicated Ang II in this process: 1) ACE inhibitors have been shown to improve left ventricular function of patients with severe congestive heart failure. 35 2) In spontaneously hypertensive rats, treatment with an ACE inhibitor caused a reversal of interstitial fibrosis and collagen accumulation.36 3) Treatment with an ACE inhibitor prevented myocardial fibrosis in a rat model of renovascular hypertension." These studies have not established whether the beneficial effects of ACE inhibition are due to a reduction in preload and afterload or whether Ang II also exerts a direct effect on the cardiac remodeling process via stimulation of fibroblasts. Weber and coworkers34,37 have reported data suggesting that Ang II can stimulate in vivo fibrosis and collagen accumulation in rat hearts, independent of an increase in afterload. The results of our study support the hypothesis that Ang II directly stimulates fibroblasts to cause interstitial remodeling. Ang II has been implicated in the development of the neonatal pig heart.38,39 Treatment of piglets with an ACE inhibitor or losartan resulted in a decrease in the left ventricle/body weight ratio, RNA content, total RNA, and protein of the left ventricle when compared with vehicle-treated animals. In addition, treatment with an ACE inhibitor decreased ribosome formation and total protein synthesis. These data suggest that Ang II is an important factor in the growth of the neonatal heart. Indirect fluorescent immunocytochemistry revealed some contamination of the cardiac fibroblast cultures with VSMCs. Therefore, one might argue that VSMCs contributed to the observed Ang II binding and the effects of Ang II on cellular growth. Several lines of evidence argue against this: 1) Total binding capacity of the fibroblast cultures for Ang II was twofold to fivefold greater than what was observed for cultured VSMCs.40 2) In contrast to the proliferative effect of Ang II reported in the present study, VSMCs exhibit a hypertrophic response to Ang 11.30 3) Preliminary studies indicate that protein kinase C activation contributes to the observed Ang II effects on the growth of cardiac fibroblasts, consistent with the finding that PDB also enhanced [3H] thymidine incorporation in our cultures; in contrast, rat VSMCs were reported not to respond to phorbol ester stimulation with enhanced DNA synthesis.41 It is also unlikely that contaminating cardiomyocytes contributed to the observed growth-promoting effects of Ang II, since enriched cultures of cardiomyocytes exhibit primarily a hypertrophic growth response to Ang 11.9,10 In summary, results of the present study demonstrate that cultured cardiac fibroblasts possess a single class of high-affinity G protein-linked AT1 receptors that are abundant and are coupled with stimulated increases in intracellular calcium and a proliferative response. Ang II enhanced incorporation of precursors into protein, RNA, and DNA and increased total protein, DNA, and cell number, whereas no effect was observed on cell area. These findings are consistent with the hypothesis that fibroblasts are a target for Ang II in the intact heart and may contribute to the Ang TI-induced remodeling of the cardiac interstitium, which is associated with a variety of physiological and pathological conditions. Further studies are required to define the intracellular pathways involved in the Ang TI-induced growth response and to assess whether Ang II regulates the genes involved in extracellular matrix production or remodeling.
